Clinical Characteristics and Spermatogenesis in Patients with Congenital Hypogonadotropic Hypogonadism Caused by FGFR1 Mutations

Table 3

Sperm production during therapy.

Groups	FGFR1 mutation (n = 14)	Mutation-negative (n = 24)
Mean follow-up time (months)	26.36 ± 8.54	22.54 ± 8.74	0.199
Cumulative success rate of achieving first sperm appearance in 1 year	35.71%	68.75%	0.047
Cumulative success rate of achieving first sperm appearance in 2 years	75.89%	82.14%	0.160
Testicular volume (mL)	7.00 (4.75–12.00) (n = 14)	10.56 ± 4.82 (n = 24)	0.098
Testosterone (ng/dL)	366.02 ± 167.03 (n = 14)	362.27 ± 212.86 (n = 24)	0.956
Testosterone in pulsatile GnRH therapy (ng/dL)	286.95 ± 130.11 (n = 4)	304.54 ± 167.03 (n = 13)	0.857
Testosterone in gonadotropin therapy (ng/dL)	397.65 ± 189.78 (n = 10)	431.76 ± 247.42 (n = 11)	0.729
FSH in GnRH pulsatile therapy (IU/L)	9.77 ± 6.20 (n = 4)	9.75 ± 4.01 (n = 13)	0.993
LH in GnRH pulsatile therapy (IU/L)	8.46 ± 3.31 (n = 4)	7.59 ± 4.07 (n = 13)	0.737